Tags

Type your tag names separated by a space and hit enter

Effects of Paliperidone Palmitate on Healthcare Utilization and Costs for Patients with Schizophrenia: A Claim-based Mirror-image Study in South Korea.
Clin Psychopharmacol Neurosci. 2020 May 31; 18(2):303-310.CP

Abstract

Objective

Long-acting injectable (LAI) antipsychotics, such as paliperidone palmitate (PP), are known to improve treatment adherence in patients with schizophrenia, which can lead to reductions in relapse and hospitalization rates. However, relatively few studies have demonstrated the economic impact of LAIs, especially in Asian populations.

Methods

We conducted a claim-based mirror-image study to explore changes in healthcare utilization and associated costs, among 1,272 South Korean patients with schizophrenia (ICD-10-CM code F20), between the 1-year periods before and after the initiation of PP treatment.

Results

Patients accessed outpatient services more frequently after versus before starting PP treatment, with the number of prescription days increasing by 133.45 (p < 0.0001) and the associated costs increasing by USD 1,497.15 (p < 0.0001). The number of admission days was reduced by 11.33 after starting PP treatment (p < 0.0001) and the associated costs were reduced by USD 1,220.75 (p < 0.0001). However, admission cost savings were different according to patients' oral drug compliance. The daily dosages for benztropine, procyclidine, and propranolol decreased, showing that there were fewer side-effects after PP-treatment (p < 0.0001).

Conclusion

Although the high acquisition cost of PP has been regarded as an obstacle to its clinical use, our results imply that the high prescription costs for PP may be counterbalanced by the reduced admission costs associated with its use. Economic outcomes for patients treated with LAIs should be investigated further to help healthcare decision-makers and providers to determine the value of LAIs relative to other treatment medications.

Authors+Show Affiliations

Emotional Information and Communication Technology Association, Seoul, Korea.Health Insurance Review and Assessment Service, Wonju, Korea. Department of Psychiatry, Hallym University Hangang Sacred Heart Hospital, College of Medicine, Hallym University, Korea.Department of Psychiatry, Seoul National University Hospital. Department of Psychiatry, Institute of Human Behavioral Medicine in SNU-MRC, Seoul National University College of Medicine, Seoul, Korea.Emotional Information and Communication Technology Association, Seoul, Korea.Department of Psychiatry, Hallym University Sacred Heart Hospital, College of Medicine, Hallym University, Anyang, Korea.Department of Psychiatry, Hallym University Sacred Heart Hospital, College of Medicine, Hallym University, Anyang, Korea.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32329310

Citation

Lee, Dasom, et al. "Effects of Paliperidone Palmitate On Healthcare Utilization and Costs for Patients With Schizophrenia: a Claim-based Mirror-image Study in South Korea." Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology, vol. 18, no. 2, 2020, pp. 303-310.
Lee D, Lee BC, Choi SH, et al. Effects of Paliperidone Palmitate on Healthcare Utilization and Costs for Patients with Schizophrenia: A Claim-based Mirror-image Study in South Korea. Clin Psychopharmacol Neurosci. 2020;18(2):303-310.
Lee, D., Lee, B. C., Choi, S. H., Kang, D. H., Jon, D. I., & Jung, M. H. (2020). Effects of Paliperidone Palmitate on Healthcare Utilization and Costs for Patients with Schizophrenia: A Claim-based Mirror-image Study in South Korea. Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology, 18(2), 303-310. https://doi.org/10.9758/cpn.2020.18.2.303
Lee D, et al. Effects of Paliperidone Palmitate On Healthcare Utilization and Costs for Patients With Schizophrenia: a Claim-based Mirror-image Study in South Korea. Clin Psychopharmacol Neurosci. 2020 May 31;18(2):303-310. PubMed PMID: 32329310.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of Paliperidone Palmitate on Healthcare Utilization and Costs for Patients with Schizophrenia: A Claim-based Mirror-image Study in South Korea. AU - Lee,Dasom, AU - Lee,Boung Chul, AU - Choi,Soo-Hee, AU - Kang,Do-Hyung, AU - Jon,Duk-In, AU - Jung,Myung Hun, PY - 2019/10/01/received PY - 2019/12/05/revised PY - 2019/12/18/accepted PY - 2020/4/25/entrez PY - 2020/4/25/pubmed PY - 2020/4/25/medline KW - Cost comparison. KW - Hospitalization KW - Mirror-image study KW - Prescriptions SP - 303 EP - 310 JF - Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology JO - Clin Psychopharmacol Neurosci VL - 18 IS - 2 N2 - Objective: Long-acting injectable (LAI) antipsychotics, such as paliperidone palmitate (PP), are known to improve treatment adherence in patients with schizophrenia, which can lead to reductions in relapse and hospitalization rates. However, relatively few studies have demonstrated the economic impact of LAIs, especially in Asian populations. Methods: We conducted a claim-based mirror-image study to explore changes in healthcare utilization and associated costs, among 1,272 South Korean patients with schizophrenia (ICD-10-CM code F20), between the 1-year periods before and after the initiation of PP treatment. Results: Patients accessed outpatient services more frequently after versus before starting PP treatment, with the number of prescription days increasing by 133.45 (p < 0.0001) and the associated costs increasing by USD 1,497.15 (p < 0.0001). The number of admission days was reduced by 11.33 after starting PP treatment (p < 0.0001) and the associated costs were reduced by USD 1,220.75 (p < 0.0001). However, admission cost savings were different according to patients' oral drug compliance. The daily dosages for benztropine, procyclidine, and propranolol decreased, showing that there were fewer side-effects after PP-treatment (p < 0.0001). Conclusion: Although the high acquisition cost of PP has been regarded as an obstacle to its clinical use, our results imply that the high prescription costs for PP may be counterbalanced by the reduced admission costs associated with its use. Economic outcomes for patients treated with LAIs should be investigated further to help healthcare decision-makers and providers to determine the value of LAIs relative to other treatment medications. SN - 1738-1088 UR - https://www.unboundmedicine.com/medline/citation/32329310/Effects_of_Paliperidone_Palmitate_on_Healthcare_Utilization_and_Costs_for_Patients_with_Schizophrenia:_A_Claim-based_Mirror-image_Study_in_South_Korea L2 - http://www.cpn.or.kr/journal/journal_view.html?year=2020&vol=18&num=2&page=303 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.